Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774670 | 0.83 | PTGS2 (0.64) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL17878838 | 0.80 | PTGS2 (0.71) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL25150436 | 0.78 | PTGS2 (0.64) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL13114284 | 0.78 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5551731 | 0.78 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14422875 | 0.78 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL16093186 | 0.76 | PTGS2 (0.64) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14429592 | 0.74 | PTGS2 (0.63) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL6120463 | 0.74 | PTGS2 (0.56) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14163956 | 0.74 | PTGS2 (0.56) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20080306146-A1 | Dosing Regimens for Cox-2 Inhibitor | AMOREPACIFIC CORPORATION (KR) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306146-A1 | Dosing Regimens for Cox-2 Inhibitor | PTGES2, PTGS2, PTGER2 | PTGS2 2/4885PTGS1 4/4885ABCC4 3272/4885 |
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | PTGS2, CA2, PTGES2 | PTGS2 1/4885PTGS1 4/4885ABCC4 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.